LCZ696 (Valsartan/sacubitril) is a combination drug for use in heart failure developed by Novartis. It consists of the angiotensin receptor blocker valsartan and the neprilysin inhibitor sacubitril, in a 1:1 mixture by molecule count. It may be used instead of an ACE inhibitor or an angiotensin receptor blocker in people with heart failure with reduced ejection fraction. The combination is sometimes described as an "angiotensin receptor-neprilysin inhibitor" (ARNi).
It was approved under the FDA's priority review process on July 7, 2015. It is also approved in Europe.
We produce a series of complete intermediates for LCZ696, intermediate I (CAS No. 1426129-50-1) and intermediate II (CAS No. 1012341-50-2) etc.
All of our products are with stable production and strict quality control, making sure your experience with Sunshine Biotech is always enriching, satisfying and fulfilling.
Lcz696 Intermediates,Cas 1426129-50-1,Cas 1012341-50-2,High Purity Lcz696 Intermediate
Nanjing Sunshine Biotech Co., Ltd , http://www.sunshine-bio.com